Danaher Management
Management criteria checks 3/4
Danaher's CEO is Rainer Blair, appointed in Sep 2020, has a tenure of 4.17 years. total yearly compensation is $20.90M, comprised of 6.2% salary and 93.8% bonuses, including company stock and options. directly owns 0.014% of the company’s shares, worth $22.63M. The average tenure of the management team and the board of directors is 5.8 years and 14.5 years respectively.
Key information
Rainer Blair
Chief executive officer
US$20.9m
Total compensation
| CEO salary percentage | 6.2% |
| CEO tenure | 4.2yrs |
| CEO ownership | 0.01% |
| Management average tenure | 5.8yrs |
| Board average tenure | 14.5yrs |
Recent management updates
Recent updates
Understanding Danaher's Cautiousness
Oct 25Is There Now An Opportunity In Danaher Corporation (NYSE:DHR)?
Sep 28
Danaher Q3 Preview: Market Share Gains In Molecular Testing
Sep 25Is Danaher Corporation (NYSE:DHR) Trading At A 32% Discount?
Sep 12Here's Why Danaher (NYSE:DHR) Can Manage Its Debt Responsibly
Aug 28Danaher: Lofty Price, Bright Future
Aug 22Danaher Corporation's (NYSE:DHR) Price In Tune With Earnings
Aug 13Danaher: Valuation Now Too High Even Compared To Own High Standards
Jul 16What Is Danaher Corporation's (NYSE:DHR) Share Price Doing?
Jun 23Mar Vista - Danaher: Headwinds Are Primarily Cyclical, Growth To Regain Momentum
Jun 20Is Danaher Corporation (NYSE:DHR) Worth US$263 Based On Its Intrinsic Value?
Jun 05Is Danaher (NYSE:DHR) A Risky Investment?
May 21It's Unlikely That Danaher Corporation's (NYSE:DHR) CEO Will See A Huge Pay Rise This Year
May 01Value Vs. Growth? Danaher Says Why Not Both?
Apr 25Danaher: All In On Life Sciences, And Market Update
Mar 27Is Now An Opportune Moment To Examine Danaher Corporation (NYSE:DHR)?
Mar 11Danaher Corporation's (NYSE:DHR) Price Is Out Of Tune With Earnings
Feb 10Bull Case Confirmed: Danaher Is Still One Of The Best Stocks To Buy Long-Term
Jan 30Is Danaher (NYSE:DHR) Using Too Much Debt?
Jan 12My Top 2024 Stock Pick: Danaher
Dec 27Danaher: Poised For Long-Term Growth Despite Near-Term Hurdles
Nov 26RGA Investment Advisors - Danaher: Purity In The Crown Jewel Of Bioprocessing
Nov 19Why Danaher Is One Of My Favorite Long-Term Investments
Oct 26Danaher: Short-Term Headwinds, But Long-Term Tailwinds
Oct 17Should Danaher Investors Sell New Veralto Shares?
Oct 02Danaher Corporation's (NYSE:DHR) Intrinsic Value Is Potentially 18% Below Its Share Price
Sep 30Danaher: A Lost Year
Aug 30Third Point - Danaher: Don't Be Surprised If Growth Rate Moves To Low Teens
Aug 02Danaher: A Compounding Icon At A Fair Price
Jul 25These 4 Measures Indicate That Danaher (NYSE:DHR) Is Using Debt Reasonably Well
Jul 13Calculating The Intrinsic Value Of Danaher Corporation (NYSE:DHR)
Jun 28Danaher: Seizing The Buying Opportunity In A Temporary Bioprocessing Slump
Jun 22At US$238, Is It Time To Put Danaher Corporation (NYSE:DHR) On Your Watch List?
Jun 15Danaher: A Great Chance To Buy This Long-Term Compounder
May 23With EPS Growth And More, Danaher (NYSE:DHR) Makes An Interesting Case
Apr 26CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 27 2024 | n/a | n/a | US$4b |
| Jun 28 2024 | n/a | n/a | US$4b |
| Mar 29 2024 | n/a | n/a | US$4b |
| Dec 31 2023 | US$21m | US$1m | US$4b |
| Sep 29 2023 | n/a | n/a | US$4b |
| Jun 30 2023 | n/a | n/a | US$5b |
| Mar 31 2023 | n/a | n/a | US$6b |
| Dec 31 2022 | US$20m | US$1m | US$6b |
| Sep 30 2022 | n/a | n/a | US$7b |
| Jul 01 2022 | n/a | n/a | US$6b |
| Apr 01 2022 | n/a | n/a | US$6b |
| Dec 31 2021 | US$17m | US$1m | US$5b |
| Oct 01 2021 | n/a | n/a | US$6b |
| Jul 02 2021 | n/a | n/a | US$5b |
| Apr 02 2021 | n/a | n/a | US$5b |
| Dec 31 2020 | US$10m | US$949k | US$4b |
| Oct 02 2020 | n/a | n/a | US$3b |
| Jul 03 2020 | n/a | n/a | US$3b |
| Apr 03 2020 | n/a | n/a | US$3b |
| Dec 31 2019 | US$7m | US$840k | US$2b |
| Sep 27 2019 | n/a | n/a | US$2b |
| Jun 28 2019 | n/a | n/a | US$2b |
| Mar 29 2019 | n/a | n/a | US$2b |
| Dec 31 2018 | US$5m | US$700k | US$2b |
| Sep 28 2018 | n/a | n/a | US$3b |
| Jun 29 2018 | n/a | n/a | US$3b |
| Mar 30 2018 | n/a | n/a | US$3b |
| Dec 31 2017 | US$4m | US$625k | US$2b |
Compensation vs Market: Rainer's total compensation ($USD20.90M) is above average for companies of similar size in the US market ($USD12.73M).
Compensation vs Earnings: Rainer's compensation has been consistent with company performance over the past year.
CEO
Rainer Blair (60 yo)
4.2yrs
Tenure
US$20,903,282
Compensation
Mr. Rainer M. Blair serves as an Independent Non-Executive Director at Nestlé S.A. since April 20, 2023. He serves as President, Chief Executive Officer and Director at Danaher Corporation since September...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Chairman | 41.8yrs | no data | 6.02% $ 10.0b | |
| President | 4.2yrs | US$20.90m | 0.014% $ 22.6m | |
| Co-Founder & Director | 41.8yrs | no data | 4.86% $ 8.1b | |
| CFO & Executive VP | 5.8yrs | US$7.50m | 0.0053% $ 8.8m | |
| Senior VP & Chief Science Officer | 3.9yrs | US$7.20m | 0.00037% $ 616.9k | |
| Senior Vice President of Human Resources | 2.6yrs | US$5.25m | 0.00015% $ 250.1k | |
| VP & Chief Accounting Officer | 2.8yrs | no data | 0.00081% $ 1.4m | |
| Vice President of Investor Relations | no data | no data | no data | |
| Senior VP | 8.8yrs | US$3.56m | 0.0028% $ 4.7m | |
| Senior Vice President of Corporate Development | 14.8yrs | no data | 0.0033% $ 5.5m | |
| Senior Vice President of Strategic Development | 10.5yrs | no data | 0.0067% $ 11.1m | |
| Executive VP of Biotechnology Group & CEO of Cytiva | less than a year | no data | 0.0020% $ 3.4m |
5.8yrs
Average Tenure
57yo
Average Age
Experienced Management: DHR's management team is seasoned and experienced (5.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Chairman | 41.8yrs | no data | 6.02% $ 10.0b | |
| President | 4.2yrs | US$20.90m | 0.014% $ 22.6m | |
| Co-Founder & Director | 41.8yrs | no data | 4.86% $ 8.1b | |
| Independent Director | 25.8yrs | US$338.13k | 0.011% $ 18.8m | |
| Independent Director | 21.3yrs | US$351.13k | 0.0054% $ 9.0m | |
| Independent Director | 15.8yrs | US$338.13k | 0.0024% $ 3.9m | |
| Independent Director | 7.8yrs | US$318.13k | 0% $ 0 | |
| Member of Scientific Advisory Board | 3.6yrs | no data | no data | |
| Lead Independent Director | 18.9yrs | US$382.13k | 0.0057% $ 9.5m | |
| Independent Director | 13.2yrs | US$318.13k | 0% $ 0 | |
| Independent Director | 5yrs | US$318.13k | 0% $ 0 | |
| Director | 5yrs | US$318.13k | 0% $ 0 |
14.5yrs
Average Tenure
64yo
Average Age
Experienced Board: DHR's board of directors are seasoned and experienced ( 14.5 years average tenure).